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Abstract
Oxygen availability falls with ascent to altitude and also as aObjective: 
consequence of critical illness. Because cellular sequelae and adaptive
processes may be shared in both circumstances, high altitude exposure
(‘physiological hypoxia’) assists in the exploration of the response to
pathological hypoxia. We therefore studied the response of healthy participants
to progressive hypobaric hypoxia at altitude. The primary objective of the study
was to identify differences between high altitude inhabitants (Sherpas) and
lowland comparators.
 We performed an observational cohort study of human responses toMethods:
progressive hypobaric hypoxia (during ascent) and subsequent normoxia
(following descent) comparing Sherpas with lowlanders. Studies were
conducted in London (35m), Kathmandu (1300m), Namche Bazaar (3500m)
and Everest Base Camp (5300m). Of 180 healthy volunteers departing from
Kathmandu, 64 were Sherpas and 116 were lowlanders. Physiological,
biochemical, genetic and epigenetic data were collected. Core studies focused
on nitric oxide metabolism, microcirculatory blood flow and exercise
performance. Additional studies performed in nested subgroups examined
mitochondrial and metabolic function, and ventilatory and cardiac variables. Of
the 180 healthy participants who left Kathmandu, 178 (99%) completed the
planned trek. Overall, more than 90% of planned testing was completed.
Forty-four study protocols were successfully completed at altitudes up to and
including 5300m. A subgroup of identical twins (all lowlanders) was also
studied in detail.
 This programme of study (Xtreme Everest 2) will provide a richConclusion:
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 This programme of study (Xtreme Everest 2) will provide a richConclusion:
dataset relating to human adaptation to hypoxia, and the responses seen on
re-exposure to normoxia. It is the largest comprehensive high altitude study of
Sherpas yet performed. Translational data generated from this study will be of
relevance to diseases in which oxygenation is a major factor.
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Introduction
A wide range of pathologies can lead to deterioration of a patient 
such that they require admission to a critical care unit. Critically 
ill patients are therefore a heterogeneous group of severely ill indi-
viduals, in whom hypoxaemia (a lack of oxygen in arterial blood) 
is common and may subsequently lead to cellular hypoxia1. The 
resulting cellular dysfunction may cause organ damage, and in 
some cases death2. Traditional management of established critical 
illness, based on efforts to increase convective oxygen delivery 
through augmented cardiac output, haemoglobin concentration and 
oxygenation, does not appear to improve outcomes3. Additionally 
excessive oxygen therapy may cause harm4,5. Consequently the role 
of alternative potential therapeutic targets such as the microcircu-
lation, mitochondrial activity and nitric oxide (NO) are becoming 
increasingly more popular as alternative strategies6–9. Permissive 
hypoxaemia has also been proposed as a viable option for critically 
ill patients, to avoid the harms associated with invasive methods of 
restoring normoxaemia in the critically ill10.
Understanding the mechanisms of human hypoxic adaptation in 
the context of critical illness is difficult. The wide range of underlying 
diseases and the complexity of treatment interactions with physiology 
make structured experiments challenging. The study of human 
responses to hypoxia occurring as a consequence of hypobaria at 
high altitude may be used as an alternative method of exploring 
elements of the pathophysiology of critical illness1,11,12. Studying 
healthy individuals progressively exposed to hypobaric hypoxia 
defines beneficial adaptive responses and may identify candidate 
pathways in the critically ill. Animal models, often proposed as 
being a suitable alternative to large-scale field studies, fail to match 
the complexity of human physiology in the critically ill patient13, 
and discordance between multiple models has been described14.
In 2007, the University College London (UCL) Centre for Alti-
tude, Space and Extreme Environment Medicine (CASE Medicine) 
conducted the largest study of human volunteers at high altitude, 
Caudwell Xtreme Everest (CXE)12,15. Resulting data have empha-
sized the need for studying the microcirculation16–18, NO formation 
and metabolism19, and mitochondrial biology20–22. A further research 
programme (Xtreme Everest 2 (XE2)) was therefore proposed to 
address this23. XE2 was designed to study the physiological (espe-
cially microcirculatory, mitochondrial, NO-related metabolic and 
epigenetic) responses to hypobaric hypoxia in native lowlanders, 
and compare them to those in Sherpas23. Sherpas are descended from 
an ancestral high altitude population resident on the Tibetan plateau 
for over 500 generations24. Such high altitude populations show evi-
dence of genetic selection25–29 that may underpin their anecdotally 
reported extraordinary tolerance to hypoxia. Their phenotype may 
therefore hold the key to successful hypoxic adaptation in humans.
We describe the design and conduct of XE2, our approach to high 
altitude translational research, and discuss the strengths and weak-
nesses of this programme of investigation.
Protocol
XE2 (December 2012 to May 2013) was undertaken by the 
Xtreme Everest Oxygen Research Consortium (XE-ORC), which 
comprises a partnership between the UK’s UCL CASE Medicine, 
the University of Southampton Centre for Human Integrative 
Physiology (CHiP), and Duke University Medical Centre (DUMC) 
in the USA.
Ethical approval
The study design, risk management plan and protocols were 
approved (in accordance with the declaration of Helsinki) both by 
the UCL Research Ethics Committee and the Nepal Health Research 
Council (NHRC).
Enrolment and informed consent
All potential participants, recruited through word of mouth and 
advertisement, were given written information about the study. Our 
Nepali Research Leader (RKBC) translated this locally in Nepal. 
Opportunities for questions, in person or over the telephone, were 
offered at multiple stages in both countries, and all participants sub-
mitted written consent for participation in the studies. At all stages 
throughout the expedition, independent translators were present to 
allow for communication between Sherpas and investigators.
Medical screening
Eligible participants were lowland children aged 8 to 17 years, or 
adults (aged 18 years or above) of either lowland or Sherpa origin. 
For the lowland participants, an independent expert experienced 
in mountain medicine identified those fit to travel to altitude by 
reviewing a health-questionnaire (supplementary material) and tele-
phone interviews as required. The forms of those selected were then 
screened by the expedition Chief Medical Officer (GGK) to con-
firm fitness both to travel to altitude, and to participate in research. 
Potential participants considered ‘at risk’ were either telephoned or 
reviewed in person by GGK. Where appropriate, and with permis-
sion, the participant’s medical practitioner was contacted. Those with 
significant cardiac or respiratory disease (e.g. severe chronic obstructive 
airway disease, ischemic heart disease with angina, or symptomatic 
heart failure) were excluded. For the Sherpa subjects, two doctors 
performed a pre-recruitment screening interview in Nepali based on 
the health-questionnaire. One doctor was a local Nepali (RKBC) and 
one an expert experienced in mountain medicine and XE2 investiga-
tor (DL/MG) who confirmed fitness for travel to altitude and research. 
As all participants would be undergoing cardiopulmonary exercise 
testing (CPET), additional exclusion criteria based on the American 
Thoracic Society/American College of Chest Physicians guidelines 
for clinical exercise testing were also adhered to30.
Medical safety
At each laboratory, an independent Medical Officer (MO) was 
responsible for decisions relating to the participants involvement 
with research protocols, the administration of medication and 
ascent or descent from their current altitude. Participants were rec-
ommended not to self-medicate, but to consult either the site MO, 
or their trek leader when between laboratory sites. In order to stand-
ardize medical care, clear guidelines for common altitude and non-
altitude related conditions were formulated prior to departure, and 
adhered to. Medication use was recorded by the individual (in a 
standardized daily diary) and by the trek leader or MO.
Study participants
In total, 187 participants were selected for inclusion in the study 
and underwent baseline testing. Sherpas were defined as direct 
descendants (for two generations) of Nepali Sherpas, drawn from 
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communities in the Solukhumbu and Rowaling valleys. Sherpa par-
ticipants were recruited by word of mouth through local community 
contacts and were required to have evidence of two generations of 
all Sherpa ancestors (parents and grand-parents). A detailed altitude 
history was then taken from all Sherpa participants including their 
altitude in utero, at birth, during childhood, in adulthood, and for 
the 12 months preceding XE2. Lowlanders were recruited in the 
UK; all were born and lived below 1000m, and were not from a 
native high altitude population (e.g. Tibetan, Andean, Ethiopian). 
They included European, American and South African participants. 
Lowlanders were divided into four cohorts: 
•   Core - eligible for all studies; eight of these participants were 
monozygotic twins (four pairs), for a pilot epigenetics study.
•   Nitrate metabolism - allocated only to be involved in a study 
of whole body NO production.
•   Investigators - who conducted the studies and remained at 
altitude for the duration of the expedition permitting studies of 
exposure to chronic hypoxia.
•   Children - who took part in the Young Everest 2 Study (YES2) 
expedition linked to XE2 in which children ascended to Nam-
che Bazaar (NB) to participate in a programme of non- invasive 
studies. YES2 will not be discussed further in this manuscript.
Potential investigators were sourced through word of mouth at 
CASE Medicine events and interviewed prior to their appointment 
(EGK, DM, KM).
All participants were required to provide baseline information that 
included details of previous altitude exposure and the occurrence 
of any altitude-related illnesses. Importantly, within the Core and 
Investigator cohorts, some selected participants had previously taken 
part in CXE (2007), thereby allowing the evaluation of consistency 
in the individual response to an identical high altitude exposure.
Of the 187 participants that were selected for the study and under-
went baseline testing, 180 departed for high altitude investigations 
(Figure 2). Of the seven participants that withdrew from the study 
prior to ascent to altitude, six lowlanders withdrew in London 
(LDN) (three for medical reasons), and one Sherpa withdrew in 
Kathmandu (KTM). Additionally, in LDN one person did not meet 
the American Thoracic Society/American College of Chest Physi-
cians guidelines for clinical exercise testing, and was withdrawn 
from CPET prior to departure. Baseline characteristics for each 
cohort are listed in Table 1.
Of the 104 lowlanders (children excluded), and 64 Sherpas leaving 
KTM, 102 (98%) and 64 (100%) reached Everest base camp (EBC) 
respectively. Of the two who did not reach EBC, one dropped out 
at NB, and the other at Pheriche due to gastrointestinal and cardio-
vascular problems respectively. All the Investigators reached their 
allocated laboratories, however, one left EBC early for medical rea-
sons, and two for personal reasons. Two investigators left NB early 
for personal reasons, and one investigator left NB early to move to 
EBC. One investigator also arrived late at EBC.
Study setting
Baseline ‘normoxic’ (35m) data for lowlander Core and Investigator 
groups were collected at The London Clinic Hospital, from 3rd 
December 2012 to 25th January 2013. Sherpa baseline testing was 
performed in KTM (1300m; 4th March to 16th April 2013). Between 
baseline testing and trek ascent, participants remained below 3000m 
in order to avoid hypoxic exposure prior to the expedition.
Ascent profile
Participants trekked in groups of up to 14. All lowlanders flew to 
KTM and spent one night there prior to flying to Lukla (2800m). 
Similarly, Sherpas flew from KTM to Lukla at the beginning of the 
trek. In order to ensure that study participants were exposed to an 
identical pattern of hypoxia exposure, all participants followed an 
identical ascent and descent profile (Figure 1). High altitude field 
Figure 1. Ascent and descent profile for XE2 Everest Base Camp trek. Key: LDN = London, KTM = Kathmandu, NB = Namche Bazaar, 
EBC = Everest Base Camp.
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Figure 2. Break down of study cohorts showing number of participants tested. Key: NB = Namche Bazaar, EBC = Everest Base Camp.
Table 1. The mean (±SD) baseline characteristics for each 
cohort (excluding the children cohort). Key: NB = Namche 
Bazaar, EBC = Everest Base Camp.
COHORT AGE HEIGHT (cm)
WEIGHT 
(kg)
GENDER 
(% male)
Core  
(n = 69) 41.3 (13.9) 171 (10) 71.1 (13.5) 39%
EBC Investigators 
(n = 14) 30.2 (5.3) 177 (10) 75.7 (17.3) 60%
NB Investigators  
(n = 7) 30.0 (8.5) 177 (6) 69.2 (7.2) 71%
Nitrate Study  
(n = 14) 43.0 (17) 172 (9) 81.7 (16.4) 36%
Sherpas  
(n = 64) 27.9 (6.9) 160 (6) 61.3 (8.9) 47%
laboratories were situated at NB (3500m) and EBC (5300m). The 
KTM laboratory was also used for descent testing for participants 
following their return from EBC. Barometric pressure, temperature, 
and humidity data were recorded twice daily at each laboratory and 
are summarized in Table 2.
The ascent to EBC from KTM was completed over 11 days with 
incorporated rest days built in to the schedule to reduce the likeli-
hood of acute mountain sickness (AMS). This ascent profile was 
identical to the CXE profile both because it was proven safe with 
minimal participant dropouts and because it would allow compari-
son of data between the two expeditions12.
The Investigator cohort underwent a similar ascent profile to the 
rest of the participants, but then remained in situ at their relevant 
laboratories for six weeks prior to descent. By using repeated test-
ing at serial intervals, we were able to study the effects of both acute 
and chronic hypoxia on these participants. It should also be noted 
that upon their arrival at EBC, the Investigators were required to 
construct the laboratory and set up equipment, and consequently 
testing was started two days after arrival.
Laboratory testing and studies
Upon arrival at each laboratory participants all were given a camp 
safety and science brief, and individualized timetables. Within 
these, in an attempt to minimize diurnal variations in physiological 
responses, participants were tested for each study at the same time 
at each site. Furthermore as many studies required abstinence from 
caffeine and food for specific periods, fasting periods and meal 
times were clearly highlighted for each individual. Within each 
laboratory, the timetable was adhered to and subjects were tested 
for particular studies on either day one or day two. These specific 
Table 2. Mean (±SD) altitude, barometric pressure, temperature 
and humidity at each XE2 laboratory. Key: LDN = London, KTM = 
Kathmandu, NB = Namche Bazaar, EBC = Everest Base Camp.
Laboratory Altitude (m)
Barometric 
pressure 
(Millibar)
Temperature 
(°C)
Humidity 
(%)
LDN 35 1006 (2.1) 16.9 (1.8) 35.4 (6.5)
KTM 1300 868 (3.7) 23.8 (3.4) 47.4 (15.7)
NB 3500 665 (2.4) 13.9 (3.1) 72.1 (8.1)
EBC 5300 530 (2.4) 12.9 (8.2) 37.8 (17.5)
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Table 3. Core studies conducted on XE2, highlighting at which lab and in which cohorts.
Study Baseline (LDN/KTM) NB EBC
KTM 
descent
Symptom assessment
Daily diary ^ ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Acute mountain sickness questionnaire ✔Φ Ω ✖ ✔Φ Ω ✔Φ Ω
Haemoglobin and oxygen carriage
Estimated arterial oxygen content ^ ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Exercise
Maximum exercise capacity ^ ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Nitric Oxide
Saliva sampling ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Exhaled breath condensate sampling ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Exhaled nitric oxide analysis ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Oral nitrate reduction test ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Plasma sampling ^ ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Urine sampling ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Microcirculation
Venous plethysmography ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Incident dark field imaging ^ ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✔Ψ Φ Ω
Laser Doppler flowmetry ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Near-infrared spectroscopy ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✔Ψ Φ Ω
Genetic and epigenetic
Genetic sampling ^ ✔Ψ Φ Ω ✖ ✖ ✖
Epigenetic sampling ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
Ventilation
Spirometry ^ ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω
^ = Also studied on CXE
Conducted in: Ψ = Sherpas, Φ = Lowlanders (Core), Ω = Investigators
days were kept constant throughout the trek so as to control for the 
effects of acute acclimatization and responses over time. Because 
of the potential interaction between some studies, not every par-
ticipant underwent all of the studies. The XE2 research portfolio, 
detailing core studies, additional studies and those in common with 
CXE, are highlighted in Table 3 and Table 4.
Biological sample storage and transport
Blood, urine, saliva and exhaled breath condensate samples were all 
kept in -40°C freezers at each site. Muscle biopsy specimens (LDN, 
KTM and EBC) were stored in liquid nitrogen (-196°C), and then 
shipped to the UK on dry ice. All samples were brought from the 
field to KTM by helicopter and then repatriated to the UK on dry 
ice (-78°C).
Outline of analysis plan
Data analysis will follow a predetermined strategy of:
i) Description of phenotypes for each of the studies as outlined in 
Table 3 and Table 4 including plasma biomarkers and metabolomic 
analyses. This will include comparison with data obtained dur-
ing a matched ascent in the CXE 2007 study (e.g. intra-individual 
comparison of the phenotypes from individuals who were partici-
pants in XE2 and CXE) as well as sub-group analyses (e.g. twins).
ii) Comparison of phenotypic adaptations between Sherpas and 
lowlanders during ascent and descent. We hypothesise that Sherpas 
will have a phenotype at baseline that is better adapted to hypoxia 
in comparison to lowlanders, that lowlanders ascending to altitude 
will tend to converge on the Sherpa phenotype, and that the Sherpa 
baseline phenotype will be less perturbed by altitude exposure than 
the lowlander baseline phenotype.
iii) Integrative analysis of genotype-epigenome-transcriptome-
phenome across multiple datasets (XE2, CXE). The XE2 dataset 
will contribute to the accumulated Extreme Everest BioResource 
acquired during a number of high altitude research expeditions. 
Data will be incorporated into our bespoke comprehensive data-
base, which enables linkage of all data elements with meta-data 
describing the provenance of each data item through the use of 
semantic web technology. Key questions will be raised in an itera-
tive manner, driven both by a priori hypotheses and subsequently 
by data mining focused on the results obtained by unbiased outputs 
from individual ‘omics analyses.
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Table 4. Additional studies conducted on XE2, highlighting at which lab and in which cohorts.
Study Baseline (LDN/KTM) NB EBC Descent
Haemoglobin and oxygen carriage 
Haemoglobin mass analysis ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✔Ψ Φ Ω 
Exercise 
Exercise efficiency and economy ^ ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω 
Oxygen uptake kinetics ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω 
Constant power tests / critical power ✔Ω ✖ ✔Ω ✔Ω 
Nitric Oxide 
Whole body NO production ✔ξ ✖ ✔ξ ✖
Mitochondria and metabolic 
Mitochondrial function in skeletal muscle ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✔Ψ Φ Ω 
Oral glucose tolerance test ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✔Ψ Φ Ω 
Metabolomic sampling ✔Ψ Φ Ω ✔ ✔Ψ Φ Ω ✔Ψ Φ Ω 
Skeletal muscle mass ^ ✔Ω ✖ ✔Ω ✔Ω 
Catecholamine sampling ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω 
Endogenous steroid sampling ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω 
Ventilation 
Hypoxic ventilatory response ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✔Ψ Φ Ω 
Dejours procedure ✖ ✖ ✔Ψ Φ Ω ✖
Upper airway 
Extra (supra)-oesophageal reflux ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✖
Laryngoscopy ^ ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✖
Nasal saccharine testing and naso-mucociliary clearance^ ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✖
Nasal secretion sampling ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✖
Acoustic rhinometry ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✖
Sino-nasal outcome testing questionnaire ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✔Ψ Φ Ω 
Pulmonary 
Extra-vascular lung water analysis ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✔Ψ Φ Ω 
Cardiovascular 
Blood pressure variation ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✖
Heart rate variability ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✖
Neocytolysis ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✖
Iron studies ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω ✔Ψ Φ Ω 
Arterial blood gas analysis ^ ✔Ω ✖ ✔Ω ✖
Proteomic sampling ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✖
Telomere analysis ✔Ψ Φ Ω ✖ ✔Ψ Φ Ω ✖
^ = Also studied on CXE
Conducted in: Ψ = Sherpas, Φ = Lowlanders (Core), Ω = Investigators, ξ = Nitrate
Results from this study will be disseminated in peer-reviewed jour-
nals, on the Xtreme Everest website (www.xtreme-everest.co.uk) at 
scientific conferences and at public meetings.
Discussion and conclusions
We have characterized many features of the human response to 
progressive hypobaric hypoxia in a cohort of 180 individuals; 44 
individual studies being safely conducted over four locations up 
to 5300m. In addition, the response to relative re-oxygenation 
was studied. The standardized ascent protocol ensured that differ-
ences between participants reflected inter-individual variability in 
hypoxic adaptation, as opposed to variability in hypoxic exposure. 
In matching the 2007 CXE ascent profile, the data from the two 
studies may also be combined to create a single cohort. The parallel 
study of lowlanders and highlanders will permit the identification of 
beneficial phenotypic adaptations and genetic alteration (and their 
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relationships) in these groups. The study of investigators exposed 
to sustained (six weeks) hypoxia facilitated study of immediate and 
longer-term adaptive processes.
The slow ascent profile minimized symptoms of AMS, increas-
ing the number of participants successfully reaching EBC and 
available for the study. Despite good medical care, gastrointesti-
nal illness may have occasionally confounded results. However, 
the application of standardized medical protocols, with detailed 
documentation of illness and medication, will ensure this can be 
accounted for. Whilst the expedition was promoted through word 
of mouth and public advertisement, the very nature of the trek itself 
meant that participants were of a self-selected nature as enthused 
to undertake a rigorous trek. They may thus not be representative 
of the general population. Laboratories in Nepal were temporary 
as opposed to permanent structures. Temperature and pressure 
fluctuations, both having the potential to confound data obtained, 
were recorded on a daily basis (Table 2). Whilst we attempted to 
maintain a constant temperature between all laboratories through 
the use of heaters, we accept that any measured differences may 
confound the results.
We believe that the wealth of data obtained from XE2 will aid our 
understanding of the human adaptive response to hypoxia, offering 
insights that may be of value to patients suffering from sub-acute 
hypoxemia as a result of critical illness.
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 Jean-Paul Richalet
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The article by Gilbert-Kawai and co-workers presents the design of Xtreme Everest 2 expedition, which
looks like a continuation of the first Caudwell Xtreme Everest expedition led in 2007.
They present a complete description of protocols and groups of subjects. Part of the experiments concern
classical domains already explored by many scientific expeditions (exercise capacity, hemglobin,
ventilation, heart rate variability, etc..). Some aspects are more interesting and original, such as
epigenetics, microcirculation, study of twins and Sherpas, although some important information are
lacking concerning, for example the tissue studied for epigenetics, if Sherpas are involved in the
epigenetic study, etc.
Altogether, we can hope that a lot of new data will be available for a better understanding of physiological
responses to hypoxia, and a greater number of publications than for the first Xtreme Everest expedition is
expected.
The argument that was often put forward to justify this extremely complex and costly type of experimental
design is that it might be of great value for patients suffering from critical illnesses associated with
hypoxia. I think this argument is unnecessary. The study of normal persons exposed to hypoxia is, by
itself, very interesting and worthwhile, and does not need any justification. Applications to patients of what
will be found is probable but impossible to predict.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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 James E. Clark
Centre of Human & Aerospace Physiological Sciences and British Heart Foundation Excellence Centre,
Cardiovascular Division, St Thomas’ Hospital, King’s College London, London, UK
This article described the planning and undertaking of the study design for the Xtreme Everest 2 research
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This article described the planning and undertaking of the study design for the Xtreme Everest 2 research
expedition which looks at Sherpa and lowlander responses to graduated hypobaric hypoxia.
The authors are experienced in this kind on study having already worked on Xtreme Everest 1 study some
years ago. The objectives are stated clearly and the rationale for the study described with the underlying
physiology. Part of the difficulty of this kind of study is the recruitment process. It would be hard to recruit
widely for this kind of expedition as the subjects are usually self-selecting, those people who are keen to
explore and ascent to altitude. However the authors have explained their recruitment methods and the
study participant information has been shown.
The study itself is fairly straightforward and includes a gradual, measured ascent to altitude and a series
of tests undertaken prior, during and after ascent and the descent following the expedition. Within the
basic study there is a cohort of subjects taking part in the "nitrate" study, to investigate whether dietary
nitrate supplementation has an impact on hypoxic tolerance and adaptation to altitude. 
A comprehensive table of outcomes and measurements is given which shows the magnitude of the study
and the way in which the investigators aimed to separate the workload between cohorts. The measures
taken are widespread and range from skeletal muscle mitochondrial function to blood composition and
numerous cardiovascular and respiratory functional analysis for which this group of investigators have
considerable experience. 
The data from this study will be beneficial to the field of hypoxia, altitude performance and will give us a
better understanding into the adaptations found in those living at altitude. This will translate into patient
care in the clinical scenario as hypoxia and oxygen delivery can affect many in intensive care. 
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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